Lupin enters agreement with Zentiva for biosimilar commercialization

Lupin has announced a strategic arrangement with Zentiva, k.s. for the commercialization of Lupin's biosimilar Certolizumab Pegol. Under the agreement, Lupin will be responsible for the development, manufacturing, and supply of the product within the agreed territories, while Zentiva will oversee commercialization activities primarily in Europe and CIS markets. Lupin will receive non-refundable payments from Zentiva based on regulatory milestones, up to USD 50 million, including upfront fees of USD 10 million. Profits from defined markets will be shared between the two companies. The agreement excludes markets such as Australia, Japan, Brazil, Philippines, and India. This collaboration is expected to expand Lupin's market reach and provide high-quality, cost-effective biosimilars globally.